Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Multi Center Prospective Rand. Double Blind Placebo Cont. Parallel Design Study to Evaluate Safety & Efficacy of Topical Sirolimus for Cutaneous Angiofibromas in Subjects W/ Tuberous Sclerosis Complex Followed by Opt. Open Label

NCT03363763 is registered in ClinicalTrials.gov with Aucta Pharmaceuticals, Inc as lead sponsor.

NCT NCT03363763
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03363763 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Multi Center Prospective Rand. Double Blind Placebo Cont. Parallel Design Study to Evaluate Safety & Efficacy of Topical Sirolimus for Cutaneous Angiofibromas in Subjects W/ Tuberous Sclerosis Complex Followed by Opt. Open Label
Lead sponsor
Aucta Pharmaceuticals, Inc
Phase
Phase 2
Overall status
Terminated
Start date
April 12, 2017
Completion date
March 24, 2023
Enrollment
24 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

angiofibroma of face, tuberous sclerosis